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https://doi.org/10.1016/j.stemcr.2018.06.004SUMMARYDue to its lack of both innate and acquired immune responses to human cells, the NODSCIDIl2rg/ (NSG)mousemodel has become an
important tool for human stem cell research. When compared with the mouse, the rat is physiologically more similar to humans and
offers advantages in preclinical efficacy studies on human stem cells, particularly in evaluating neural, hepatic, and cardiac functions.
Therefore, we generated a human SIRPa +Prdkc/Il2rg/ rat model, denoted NSG-like (NSGL) rat, which expresses human SIRPa and
is abolished in the development of B, T, and natural killer cells. When compared with Prdkc/Il2rg/ (SG) rats, NSGL rats allow
more efficient engraftment of human cancer cells and human pluripotent stem cells. In addition, only NSGL rats, but not SG rats, can
be engrafted with human hematopoietic stem cells to reconstitute the human immune system. Therefore, NSGL rats represent an
improved xenotransplantation model for efficacy studies of human stem cells.INTRODUCTION
Immunodeficient animal models play critical roles in
biomedical research, such as in the evaluation of stem
cell functions in vivo. Severe combined immunodeficient
(SCID) mice lack an adaptive immune response due to de-
ficiencies in genes such as Prdkc (Rongvaux et al., 2014).
However, innate immune cells such as natural killer (NK)
cells and macrophages can also reject human cells trans-
planted into mice, and thus significantly reduce the
engraftment efficiency of human cells in SCID mice (Stro-
wig et al., 2011; Takenaka et al., 2007; Yamauchi et al.,
2013). These bottlenecks are resolved by the findings that
NK cells in mice do not develop after the Il2rg gene is dis-
rupted (DiSanto et al., 1995). In addition, the inhibitory re-
ceptor signal regulatory protein alpha (SIRPa), which is
primarily expressed on the surface of monocytes and mac-
rophages, is responsible for the macrophage-mediated
rejection of xenografts by sensing through the interaction
between SIRPa and CD47 (Jaiswal et al., 2009; Oldenborg
et al., 2000). Non-obese diabetic (NOD)mice harbor a poly-
morphism in the Sirpa gene that enhances the binding of
mouse SIRPa to human CD47, preventing the macro-
phage-mediated rejection of human cells in NOD mice
(Takenaka et al., 2007). The transgenic expression of
human SIRPa gene in SCID mice also improves the
engraftment of human stem cells (Strowig et al., 2011; Tak-
enaka et al., 2007; Yamauchi et al., 2013). Therefore,
NODSCIDIl2rg/ (NSG) mice represent an optimized
transplantation model for human stem cell research, espe-514 Stem Cell Reports j Vol. 11 j 514–521 j August 14, 2018 j ª 2018 The A
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context, NSG mice can be efficiently engrafted with
human HSCs to reconstitute the human immune system,
providing an important in vivomodel to study human im-
mune responses (Koboziev et al., 2015; Zhang et al., 2009).
For example, these immune system-humanized mice have
been successfully used to study human immune responses
to cells derived from human pluripotent stem cells (He
et al., 2017; Rong et al., 2014; Zhao et al., 2015).
Compared with the mouse, the rat is metabolically and
physiologically more similar to humans and is the
preferred species for modeling metabolic diseases and car-
rying out physiological, pharmacological (including phar-
macokinetics and pharmacodynamics), and toxicological
studies to provide preclinical efficacy and safety data (Flor-
esco et al., 2005; Gibbs et al., 2004; Martignoni et al., 2006)
(Blais et al., 2017; Goutianos et al., 2015). The rat is also the
preferred species to evaluate the behavioral, psychological,
and cognitive functions in response to drug treatment and
stem cell therapy of neurological diseases (Ellenbroek and
Youn, 2016; Gibbs et al., 2004; Robbins, 2017). Because
of the enormous difference between the heart rates of
mice and humans, the mouse model is inappropriate to
evaluate the functions of human stem cell-based therapy
of heart diseases. Larger animal models with slower heart
rates, such as the rat, aremore suitable for this purpose (Ter-
rovitis et al., 2010). In support of this notion, rat models
have been extensively used to evaluate the efficacy of hu-
man stem cell therapy of heart diseases, such as myocardial
infarction and heart failure (Terrovitis et al., 2010).uthor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
Additionally, compared with mice, the body size of the rat
is significantly larger, and thus allows more sophisticated
surgical procedures for stem cell transplantation and pro-
vides more blood and sample volume to evaluate the effi-
cacy of stem cell-based therapy. Therefore, the NSG rat
can serve as a better alternative to the NSG mouse for pre-
clinical evaluation of the efficacy of human stem cell-based
therapy.
While the genetic manipulation of the mouse has
become routine during the past 40 years, the genetic
manipulation of rats has been technically challenging,
and NSG rats have not yet been reported. Two recent pub-
lications described the generation of Prkdc/ (SCID) and
Il2rg/ rats, which exhibit immunodeficiency similar to
that of their mouse counterparts (Mashimo et al., 2010,
2012). However, while the Prkdc/Il2rg/ (SG) rats lack
acquired immunity (B and T cells) and NK cells, they
cannot be engrafted with human HSCs due to the macro-
phage-mediated rejection of human xenografts, as ex-
pected from mouse studies (Mashimo et al., 2012).
Therefore, it is necessary to generate NSG rats for human
stem cell research.
The breakthrough technology of CRISPR (clustered
regularly interspaced short palindromic repeat) and Cas
(CRISPR-associated) protein (CRISPR/Cas9 system) has
enabled the efficient genetic modification of various ani-
mal species, including rats. Taking advantage of the
CRISPR/Cas9 technology, we disrupted the Prkdc and
Il2rg genes in rats. We further established human SIRPa
(hSIRPa) transgenic rats via zygote injection and inter-
crossed these genetically modified rats to generate
hSIRPa+Prkdc/Il2rg/ rats, denoted NSG-like (NSGL)
rats. Compared with SG rats, NSGL rats can be more effi-
ciently engrafted with human cancer cells and human
embryonic stem cells (hESCs), but only NSGL rats can
be engrafted with human HSCs. Therefore, the NSGL
rats will have broad applications in human stem cell
research.RESULTS
Generation and Characterization of SG and NSGL Rats
To generate hSIRPa+ transgenic rats, a 200-kb bacterial arti-
ficial chromosome (BAC; RP11-993C19) harboring the
entire coding region of human SIRPa (hSIRPa) was linear-
ized and injected into rat zygotes, which were implanted
into pseudo-pregnant female rats to generate hSIRPa+
transgenic rats. Flow cytometric analysis demonstrated
the co-expression of rat Sirpa (rSirpa) and hSIRPa on the sur-
face of the leukocytes of the hSIRPa+ transgenic mice, con-
firming the successful generation of hSIRPa+ transgenic
mice (Figure S1).To generate the SCID rats, we employed CRISPR/Cas9
technology to disrupt the rat Prkdc gene. Two guide
RNAs (gRNAs) were designed to achieve the disruption
of the gene (Figure S2A). The sequencing of F1 rats indi-
cated a deletion of 95 bases in the Prkdc gene (Figure S2B).
Compared with wild-type (WT) rats, the percentage of
B and T cells was reduced in the Prkdc+/ rats (Figure S2C).
The development of B cells was abolished in the Prkdc/
rats, indicating the successful disruption of the Prkdc
gene (Figure S2C). However, there remained a small frac-
tion of CD4+ cells in the Prkdc/ rats, suggesting a leaky
mutation that retained a low level of DNA-dependent pro-
tein kinase activity similar to that found in SCID mice
(Figures S2C). The percentage of NK cells was increased
in Prkdc/ rats due to the large reduction of B and
T cells (Figure S2C).
We used a similar approach to disrupt the Il2rg gene in
the rat, leading to a 662-bp deletion of the Il2rg gene (Fig-
ures S3A and S3B). The disruption of the Il2rg gene abol-
ished the development of NK and B cells in rats and
significantly reduced the number of T cells in the rats (Fig-
ure S3C). Therefore, the Il2rg chain is required for the
development of the lymphoid lineages in rats.
To generate rats that are lacking in acquired immunity
and NK cells, we intercrossed Prkdc+/ Il2rg+/ rats to
generate SG rats. While a small fraction of T cells remained
in Prkdc/ and Il2rg/ rats, T cells were abolished in SG
rats (Figures 1A and 1B). We also introduced the hSIRPa
transgene into the SG background throughmultiple gener-
ations of intercrossing to generate NSGL rats, which ex-
press the hSIRPa in leukocytes but do not have B, T, and
NK cells (Figures 1A and 1B).
NSGL Rats Can Be More Efficiently Engrafted with
Human Cancer Cells and hESCs than SG Rats
Based on the roles of SIRPa in the macrophage-mediated
rejection of human cells, we predicted that NSGL rats could
be more efficiently engrafted with human cells. We first
compared the engraftment efficiency of human cancer
cells (H460) subcutaneously transplanted in SG and
NSGL rats. While the implanted NSGL rats rapidly devel-
oped tumors after transplantation, the implanted SG rats
developed smaller tumors with slower kinetics (Figures 2A
and 2B). Therefore, NSGL rats can be more efficiently en-
grafted with human cancer cells than SG rats.
hESCs can spontaneously form teratomas after subcu-
taneous transplantation in NSG mice (Rong et al., 2012,
2014). Therefore, we used a teratoma formation assay to
compare the engraftment efficiency of hESCs in SG and
NSGL rats. After subcutaneous transplantation, all im-
planted NSGL rats developed teratomas (Figures 2C and
2D). However, the implanted SG rats either failed to
develop teratomas or developed teratomas at a muchStem Cell Reports j Vol. 11 j 514–521 j August 14, 2018 515
Figure 1. Defective Development of B, T, and NK Cells in Various Genetically Mutant Rats
(A) NK cells, B cells, and T cells are abolished in SG (Prdkc/Il2rg/) and NSGL (hSIRPa+Prdkc/Il2rg/) rats. In addition, NSGL rats
co-expressed human SIRPa and rat SIRPa on the peripheral blood leukocytes. The genotypes are indicated on the top and cell types on the
left. The percentage of the gated cells within the CD45+ leukocytes is indicated. PBMC, peripheral blood mononuclear cells.
(B) Statistical analysis of the percentage of NK cells, B cells, and T cells in the CD45+ leukocytes in the peripheral blood of WT (N = 10), SG
(N = 14), and NSGL (N = 18) rats. Mean value ± SD are presented. p values are indicated.slower rate (Figures 2C and 2D). Therefore, NSGL rats can
be more efficiently engrafted with hESCs than SG rats.
Engraftment of Human HSCs in SG and NSGL Rats
Previous studies have shown that SGmice or rats cannot be
engrafted with human HSCs (hHSCs) to reconstitute the
human immune system (Mashimo et al., 2012). Therefore,
we tested the possibility of engrafting NSGL rats with
hHSCs by transfusing CD34+ cells derived from human
fetal liver into SG and NSGL rats pre-conditioned with
ionizing radiation. Consistent with previous findings
(Mashimo et al., 2012), none of the seven analyzed SG
rats transplantedwithCD34+ hHSCs developed human im-
mune cells up to 10 weeks after implantation (Figure 3C).
In contrast, five of the seven NSGL rats that survived the
transfusion developed human CD45+ cells in the periph-
eral blood 5 weeks after transfusion (Figure 3A). There
was an efficient reconstitution of CD19+ human B cells in516 Stem Cell Reports j Vol. 11 j 514–521 j August 14, 2018the NSGL rats transfused with human fetal liver CD34+
cells (Figures 3A and 3B). However, there was a lack of hu-
man T cells in these rats that was likely due to the absence
of human thymus required for efficient human T cell
development.
To promote T cell development in NSGL rats engrafted
with hHSCs, we transplanted a small piece of autologous
human fetal thymus under the renal capsule of pre-condi-
tioned SG and NSGL rats that were simultaneously trans-
fused with hHSCs, as we previously described to establish
the mice with a humanized immune system (He et al.,
2017; Rong et al., 2014; Zhao et al., 2015). While we could
not detect any humanCD45+ cells in six SG rats 5 weeks af-
ter being transplanted with CD34+ fetal liver cells and fetal
thymus, we detected humanCD45+ cells in six of the seven
surviving NSGL rats 5 weeks after transplantation (Fig-
ure 4A). In addition to the reconstitution of human B cells,
human T cells were also efficiently reconstituted in the
Figure 2. NSGL Rats Were More Effi-
ciently Engrafted with Human Cancer
Cells and hESCs than SG Rats
Growth curve of tumors formed by human
lung cancer cells H460 (A) and teratomas
formed by H9 hESCs (C) after subcutaneous
injection into the SG and NSGL rats. The
tumor volume was plotted against the days
after transplantation. N = 3. Mean value ±
SD are presented. Statistical analysis of the
volume and weight of the tumors formed by
H460 cells 2 weeks after transplantation (B)
or those of the teratomas formed by hESCs
at 6 weeks after transplantation (D) in SG
and NSGL rats. N = 3. p values are indicated.NSGL rats 5weeks after transplantation (Figures 4A–4D and
S4). Human NK cells and macrophages were easily detect-
able in the bone marrow of the reconstituted NSGL rats
(Figure 4C). In summary, in contrast to SG rats, NSGL rats
can be engrafted with hHSCs to develop a human immune
system.DISCUSSION
Immunodeficient animal models have become indispens-
able transplantation models in stem cell research. Among
various experimental animal species, the mouse has
become the most extensively used animal species in
biomedical research and drug development due to the
long-established feasibility of genetically modifying the
mouse genome. In this context, mouse ESCs were success-
fully established more than 40 years ago to allow efficient
genetic modification of the mouse genome in vitro (Evans
and Kaufman, 1981; Martin, 1981), and the development
of chimeric mouse technology has enabled the transmis-
sion of the genetic mutations of mouse ESCs into the
mouse germline (Wood et al., 1993). Various spontaneous
and genetically modified immunodeficient mouse models,
including nude mice, SCID mice, NSG mice, and RAG1/2-
deficient mice, have been widely used for biomedical
research (Rongvaux et al., 2013). These technical advances
have been delayed for other animal species, such as the rat
and pig, which are evolutionarily and physiologically
closer to humans than the mouse (Aitman et al., 2008;
Gibbs et al., 2004).With the accumulating knowledge of the immune re-
sponses to human xenografts in mice, it has been well es-
tablished that both acquired and innate immunity are
involved in rejecting human cells transplanted in mice
(Strowig et al., 2011; Takenaka et al., 2007; Yamauchi
et al., 2013). Several lines of immunodeficient mice
(Nude, SCID or Prkdc/, RAG1/2 deficient) are defective
in acquired immunity (Rongvaux et al., 2013). The innate
immunity mediated by NK cells and macrophages is also
required for the immune rejection of human cells, espe-
cially human stem cells (Ishikawa et al., 2005; Ito et al.,
2002, 2012). These problems are mitigated by the abolish-
ment of NK cells in Il2Rg/ mice and a mutation in the
Sirpa gene of NOD mice that prevents macrophage-medi-
ated rejection of human cells by promoting the interaction
between mouse SIRPa and human CD47 (Strowig et al.,
2011; Takenaka et al., 2007; Yamauchi et al., 2013). These
discoveries led to the generation of NSGmice that are lack-
ing in both innate and acquired immunity. Therefore, NSG
mice have become an important transplantationmodel for
human stem cell research (Rongvaux et al., 2013). Consid-
ering the significant physiological differences between the
mouse and human immune systems, NSG mice reconsti-
tuted with a functional human immune systemhave broad
applications in studying human immunity, from infection
to cancer and human stem cells (Liu et al., 2017; Rongvaux
et al., 2013).
Despite the importance of NSG mice in biomedical
research, their rat counterparts represent a better xeno-
transplantation model to evaluate the neural, cardiac,
and hepatic functions of stem cell therapy (Aitman et al.,Stem Cell Reports j Vol. 11 j 514–521 j August 14, 2018 517
Figure 3. NSGL Rats Can Be Engrafted with Human Hematopoietic Stem Cells to Develop Multi-lineage hCD45+ Human Leukocytes
(A and B) Human B cells and macrophages, but not human T cells, were readily detected within the PBMCs (A) and bone marrow (BM) (B) of
NSGL rats 5 weeks after being transfused with CD34+ human fetal liver cells. The percentage of the hCD45+ cells within the leukocyte
population is indicated in the top panel. The percentage of human B cells, T cells, and macrophages within the hCD45+ human leukocyte
population is indicated in the bottom panel. PBMC and BM of the WT rats were used as negative controls for immunostaining.
(C) Statistical analysis of the percentage of the hCD45+ cells within all leukocytes as well as the percentage of B cells and T cells within the
gated hCD45+ cell population in SG and NSGL rats transplanted with hHSCs. The engraftment rate (the number of rats with human cell
engraftment versus the total rats transplanted) is indicated. Mean values ± SD are presented.2008; Pijacka et al., 2016). Therefore, the establishment of
the NSGL rat represents a major advance in preclinical effi-
cacy studies of human stem cell-based therapy. In addition,
in contrast to SG rats, only NSGL rats can be engrafted with
human HSCs to reconstitute a human immune system.
Therefore, once the conditions to reconstitute the human
immune system in NSGL rats are optimized, we expect
that the NSGL rats and immune system-humanized rats
will become important new tools for human stem cell
research and therapeutic development.EXPERIMENTAL PROCEDURES
Genetic Manipulation of Rats
Wedisrupted the Prkdc and Il2rg genes in Sprague-Dawley (SD) rats
by injecting a pair of gRNAs and CAS9 mRNA into rat zygotes,
which were then implanted into pseudo-pregnant female SD
rats. We generated human SIRPa transgenic rats via zygote injec-
tion of BAC DNA. The rat genomic DNA used for genotyping was
isolated from a small piece of ear. All animal work was approved
by the Institutional Animal Care and Use Committee.518 Stem Cell Reports j Vol. 11 j 514–521 j August 14, 2018Cell Culture
The H9 hESCs were cultured on a CF1mouse embryonic fibroblast
feeder layer in DMEM/F12 supplemented with 20% knockout
serum replacement, 0.1 mM nonessential amino acids, 2 mMGlu-
tamax, 1% penicillin/streptomycin, 10 ng/mL basic fibroblast
growth factor, and 110 mM b-mercaptoethanol. H9 hESCs were
dissociated with collagenase type IV (1 mg/mL) and passaged on
a feeder layer with a 1:4–1:6 dilution. H460 lung cancer cells
were cultured in RPMI-1640medium supplementedwith 10% fetal
bovine serum, 2 mM Glutamax, 1% penicillin/streptomycin, and
55mM b-mercaptoethanol. All cell culture reagents were purchased
from Invitrogen unless indicated otherwise.Xenotransplantation Studies
Five-week-oldmale rats were subcutaneously injected with human
cells. The length (a) and width (b) of the tumors or teratoma were
measured with calipers, using the formula V = ab2/2 to calculate
the tumor or teratoma volume (V). Female rats 6–10 weeks old
were used for the reconstitution of the immune system by trans-
planting human HSCs and/or fetal thymus cells. After pre-condi-
tioning with sublethal (250 cGy or 200 cGy, 100 cGy/min) total
body ionizing irradiation, SG and NSGL rats were intravenously
Figure 4. The reconstitution of Human Immune System in NSGL Rats Engrafted with CD34+ Fetal Liver Cells and Autologous Fetal
Thymus
(A–C) Human B cells, T cells, and NK cells were readily detected in the PBMC (A), spleen (B), and BM (C) of NSGL rats 5 weeks after
transplantation. No reconstitution of the immune cells could be detected in SG rats up to 10 weeks after transplantation. The percentage of
hCD45+ cells within all leukocytes is indicated in the top panels. The percentage of NK cells, macrophages, B cells, and T cells within the
gated hCD45+ human leukocyte population is indicated in the bottom panels.
(D) Statistical analysis of the percentage of the hCD45+ cells within all leukocytes as well as the percentage of B cells and T cells within the
gated hCD45+ cell population in SG and NSGL rats engrafted with CD34+ fetal liver cells and autologous fetal thymus. The engraftment rate
(the number of rats with human cell engraftment versus the total rats transplanted) is indicated. Mean values ± SD are presented.transfused with 1 3 106 human CD34+ fetal liver cells with or
without implantation of human fetal thymic tissue (1mm3) under
the kidney capsule. Human fetal tissues were obtained from
Advanced Bioscience Resources (ABR) under informed consent,
and their use in this study was approved by ABR as well as
University of California, San Diego and Southern Medical Univer-
sity. Human CD34+ cells were isolated by a magnetic-activated cell
sorter separation system using anti-CD34 microbeads (Miltenyi
Biotec) as we previously described (He et al., 2017; Zhao et al.,
2015).
Flow Cytometry Analysis
The single cell suspension of rat tissues was prepared as previously
described (He et al., 2017). After the red blood cells were lysed with
ammonium-chloride-potassium buffer, the cells were stained with
human or rat leukocyte-specific antibodies and analyzedwith a BD
LSRFortessa cytometer using FlowJo software. The antibodies used
were the following: hCD45 (BD Bioscience, 561864), hCD19 (BDBioscience, 560994), hCD3 (BD Bioscience, 563423), hCD4 (BD
Bioscience, 555347), hCD8 (BD Bioscience, 555634), hCD56 (Bio-
legend, 318332), hCD14 (BD Bioscience, 557831), rCD45 (Bio-
legend, 202216), rCD45RA (Biolegend, 202318), rCD3 (Biolegend,
201403), rCD4 (Biolegend, 201516), rCD8a (Biolegend, 200610),
rCD161a (BD Bioscience, 555009), hSIRPa (Biolegend, 323810),
and rSIRPa (Biolegend, 204706).
Statistical Analysis
All statistical analyses were performed using a two-tailed Student’s
t test with GraphPad Prism 5 software. The mean ± SD and p value
are shown. p < 0.05 indicates statistical significance.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found
with this article online at https://doi.org/10.1016/j.stemcr.2018.
06.004.Stem Cell Reports j Vol. 11 j 514–521 j August 14, 2018 519
AUTHOR CONTRIBUTIONS
Y.X. designed the research. X.Y., J.H., and J.Z. performed themajor-
ity of experiments with the help of J.L., Y.L., H.W., T.J., and Q.Z.
X.Y., J.H., X.F., and Y.X. interpreted the data. X.F. and Y.X. provided
the administrative support. X.Y. and Y.X. were responsible for the
initial draft of the manuscript, whereas other authors contributed
to the final version.
ACKNOWLEDGMENTS
We thank Dr. Zhili Rong for technical advice. This study was sup-
ported by the National Natural Science Foundation of China
(nos. 815300045, 81373166, 81430032, and U1601222), a grant
from the National High-tech R&D Program (863 Program no.
2015AA020310), the leading talents of Guangdong Province Pro-
gram (no. 00201516), the Guangdong Provincial Key Laboratory
of Tumor Immunotherapy, the Guangzhou Key Laboratory of Tu-
mor Immunology Research, the South Wisdom Valley Innovative
Research Team Program (2014) no. 365, the Guangdong Province
Key Special Science and Technology Project (2015B020225004),
and a major basic research developmental project of the Natural
Science Foundation of Guangdong Province.
Received: July 22, 2017
Revised: June 4, 2018
Accepted: June 6, 2018
Published: July 5, 2018REFERENCES
Aitman, T.J., Critser, J.K., Cuppen, E., Dominiczak, A., Fernandez-
Suarez, X.M., Flint, J., Gauguier, D., Geurts, A.M., Gould, M.,
Harris, P.C., et al. (2008). Progress and prospects in rat genetics:
a community view. Nat. Genet. 40, 516–522.
Blais, E.M., Rawls, K.D., Dougherty, B.V., Li, Z.I., Kolling, G.L., Ye,
P., Wallqvist, A., and Papin, J.A. (2017). Reconciled rat and
human metabolic networks for comparative toxicogenomics and
biomarker predictions. Nat. Commun. 8, 14250.
DiSanto, J.P., Muller, W., Guy-Grand, D., Fischer, A., and Rajewsky,
K. (1995). Lymphoid development inmicewith a targeted deletion
of the interleukin 2 receptor gamma chain. Proc. Natl. Acad. Sci.
USA 92, 377–381.
Ellenbroek, B., and Youn, J. (2016). Rodentmodels in neuroscience
research: is it a rat race? Dis. Model. Mech. 9, 1079.
Evans, M.J., and Kaufman, M.H. (1981). Establishment in culture
of pluripotential cells frommouse embryos. Nature 292, 154–156.
Floresco, S.B., Geyer, M.A., Gold, L.H., and Grace, A.A. (2005).
Developing predictive animal models and establishing a preclini-
cal trials network for assessing treatment effects on cognition in
schizophrenia. Schizophr. Bull. 31, 888–894.
Gibbs, R.A.,Weinstock, G.M.,Metzker,M.L.,Muzny, D.M., Soderg-
ren, E.J., Scherer, S., Scott, G., Steffen, D., Worley, K.C., Burch, P.E.,
et al. (2004). Genome sequence of the Brown Norway rat yields in-
sights into mammalian evolution. Nature 428, 493–521.
Goutianos, G., Tzioura, A., Kyparos, A., Paschalis, V., Margaritelis,
N.V., Veskoukis, A.S., Zafeiridis, A., Dipla, K., Nikolaidis, M.G., and520 Stem Cell Reports j Vol. 11 j 514–521 j August 14, 2018Vrabas, I.S. (2015). The rat adequately reflects human responses to
exercise in blood biochemical profile: a comparative study. Physiol.
Rep. 3. https://doi.org/10.14814/phy2.12293.
He, J., Rong, Z., Fu, X., and Xu, Y. (2017). A safety checkpoint to
eliminate cancer risk of the immune evasive cells derived from hu-
man embryonic stem cells. Stem Cells 35, 1154–1161.
Ishikawa, F., Yasukawa, M., Lyons, B., Yoshida, S., Miyamoto, T.,
Yoshimoto, G., Watanabe, T., Akashi, K., Shultz, L.D., and Harada,
M. (2005). Development of functional human blood and immune
systems inNOD/SCID/Il2 receptor gamma chain(null)mice. Blood
106, 1565–1573.
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M.,
Hioki, K., Ueyama, Y., Koyanagi, Y., Sugamura, K., Tsuji, K., et al.
(2002). NOD/SCID/gamma(c)(null) mouse: an excellent recipient
mouse model for engraftment of human cells. Blood 100, 3175–
3182.
Ito, R., Takahashi, T., Katano, I., and Ito, M. (2012). Current ad-
vances in humanized mouse models. Cell. Mol. Immunol. 9,
208–214.
Jaiswal, S., Jamieson, C.H.M., Pang, W.W., Park, C.Y., Chao, M.P.,
Majeti, R., Traver, D., van Rooijen, N., and Weissman, I.L. (2009).
CD47 is upregulated on circulating hematopoietic stem cells and
leukemia cells to avoid phagocytosis. Cell 138, 271–285.
Koboziev, I., Jones-Hall, Y., Valentine, J.F., Reinoso Webb, C., Furr,
K.L., and Grisham, M.B. (2015). Use of humanized mice to study
the pathogenesis of autoimmune and inflammatory diseases.
Inflamm. Bowel Dis. 21, 1652–1673.
Liu, X., Li, W., Fu, X., and Xu, Y. (2017). The immunogenicity and
immune tolerance of pluripotent stem cell derivatives. Front.
Immunol. 8. https://doi.org/10.3389/fimmu.2017.00645.
Martignoni, M., Groothuis, G.M.M., and de Kanter, R. (2006). Spe-
cies differences between mouse, rat, dog, monkey and human
CYP-mediated drug metabolism, inhibition and induction. Expert
Opin. Drug Metab. Toxicol. 2, 875–894.
Martin, G.R. (1981). Isolation of a pluripotent cell line from early
mouse embryos cultured in medium conditioned by teratocarci-
noma stem cells. Proc. Natl. Acad. Sci. USA 78, 7634–7638.
Mashimo, T., Takizawa, A., Kobayashi, J., Kunihiro, Y., Yoshimi, K.,
Ishida, S., Tanabe, K., Yanagi, A., Tachibana, A., Hirose, J., et al.
(2012). Generation and characterization of severe combined im-
munodeficiency rats. Cell Rep. 2, 685–694.
Mashimo, T., Takizawa, A., Voigt, B., Yoshimi, K., Hiai, H., Kura-
moto, T., and Serikawa, T. (2010). Generation of knockout rats
with X-linked severe combined immunodeficiency (X-SCID) using
zinc-finger nucleases. PLoS One 5, e8870.
Oldenborg, P.A., Zheleznyak, A., Fang, Y.F., Lagenaur, C.F., Gre-
sham, H.D., and Lindberg, F.P. (2000). Role of CD47 as a marker
of self on red blood cells. Science 288, 2051–2054.
Pijacka, W., McBryde, F.D., Marvar, P.J., Lincevicius, G.S., Abdala,
A.P.L., Woodward, L., Li, D., Paterson, D.J., and Paton, J.F.R.
(2016). Carotid sinus denervation ameliorates renovascular hyper-
tension in adult Wistar rats. J. Physiol. 594, 6255–6266.
Robbins, T.W. (2017). Cross-species studies of cognition relevant to
drug discovery: a translational approach. Br. J. Pharmacol. 174,
3191–3199.
Rong, Z.L., Fu, X.M., Wang, M.Y., and Xu, Y. (2012). A scalable
approach to prevent teratoma formation of human embryonic
stem cells. J. Biol. Chem. 287, 32338–32345.
Rong, Z.L., Wang, M.Y., Hu, Z., Stradner, M., Zhu, S.Y., Kong, H.J.,
Yi, H.F., Goldrath, A., Yang, Y.G., Xu, Y., et al. (2014). An effective
approach to prevent immune rejection of humanESC-derived allo-
grafts. Cell Stem Cell 14, 121–130.
Rongvaux, A., Takizawa, H., Strowig, T., Willinger, T., Eynon, E.E.,
Flavell, R.A., and Manz, M.G. (2013). Human hemato-lymphoid
system mice: current use and future potential for medicine.
Annu. Rev. Immunol. 31, 635–674.
Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S.V.,
Teichmann, L.L., Saito, Y., Marches, F., Halene, S., Palucka, A.K.,
et al. (2014). Development and function of human innate immune
cells in a humanized mouse model. Nat. Biotechnol. 32, 364–372.
Strowig, T., Rongvaux, A., Rathinam, C., Takizawa, H., Borsotti, C.,
Philbrick, W., Eynon, E.E., Manz, M.G., and Flavell, R.A. (2011).
Transgenic expression of human signal regulatory protein alpha
in Rag2(-/-)gamma(-/-)(c) mice improves engraftment of human
hematopoietic cells in humanized mice. Proc. Natl. Acad. Sci.
USA 108, 13218–13223.Takenaka, K., Prasolava, T.K., Wang, J.C., Mortin-Toth, S.M., Kha-
louei, S., Gan, O.I., Dick, J.E., and Danska, J.S. (2007). Polymor-
phism in Sirpa modulates engraftment of human hematopoietic
stem cells. Nat. Immunol. 8, 1313–1323.
Terrovitis, J.V., Smith, R.R., andMarba´n, E. (2010). Assessment and
optimization of cell engraftment after transplantation into the
heart. Circ. Res. 106, 479.
Wood, S.A., Allen, N.D., Rossant, J., Auerbach, A., and Nagy, A.
(1993). Non-injection methods for the production of embryonic
stem cell-embryo chimaeras. Nature 365, 87–89.
Yamauchi, T., Takenaka, K., Urata, S., Shima, T., Kikushige, Y., Iwa-
moto, C., Miyamoto, T., and Akashi, K. (2013). Polymorphic SIRPA
is the genetic determinant for nod-based mouse lines to achieve
efficient human cell engraftment. Exp. Hematol. 41, S34.
Zhang, B.J., Duan, Z.Y., and Zhao, Y. (2009). Mouse models with
human immunity and their application in biomedical research.
J. Cell. Mol. Med. 13, 1043–1058.
Zhao, T., Zhang, Z.N., Westenskow, P.D., Todorova, D., Hu, Z., Lin,
T., Rong, Z., Kim, J., He, J.,Wang,M., et al. (2015). Humanizedmice
reveal differential immunogenicity of cells derived from autolo-
gous induced pluripotent stem cells. Cell Stem Cell 17, 353–359.Stem Cell Reports j Vol. 11 j 514–521 j August 14, 2018 521
